Roger Hajjar News Today

GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy 

Spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.

(This Aug. 12 story has been corrected to state that ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9

Baby Ben Kutschke was diagnosed at 3 months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.

Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally. It leaves children too weak to... -Today at 05:00 am- MarketScreener

Zolgensma has been given to more than 3,000 children globally

LOS ANGELES - Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally. It leaves children too weak to walk, talk, swallow or even breathe. So when in 2021 his parents heard about Zolgensma – a one-time therapy costing millions of dollars that...

Hitachi Ltd has partnered with Brigham and Women's Hospital (BWH) to establish a joint research initiative focused on gene and cell therapy (GCT) for conquering challenging diseases. Click to read more...

FOR IMMEDIATE RELEASE Hitachi forms strategic research collaboration with Mass General Brigham in the field of...

How Genomics can revolutionise healthcare?